Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection in 2015

AASLD/IDSA Guidance Panel, 2015, Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus, Hepatology, 62, 932, 10.1002/hep.27950 Anon, 2014 EASL, 2015, Recommendations on treatment of hepatitis C 2015, J Hepatol, 63, 199, 10.1016/j.jhep.2015.03.025 Myers, 2015, An update on the management of chronic hepatitis C: 2015 consensus guidelines from the Canadian Association for the Study of the Liver, Can J Gastroenterol Hepatol, 29, 19, 10.1155/2015/692408 Berden, 2014, Dutch guidance for the treatment of chronic hepatitis C virus infection in a new therapeutic era, Neth J Med, 72, 388 NICE technology appraisal guidance 330, 2015 Puri, 2014, Consensus statement of HCV task force of the Indian National Association for Study of the Liver (INASL). Part I: Status report of HCV infection in India, J Clin Exp Hepatol, 4, 104 Puri, 2014, Consensus statement of HCV task force of the Indian National Association for Study of the Liver (INASL). Part II: INASL recommendations for management of HCV in India, J Clin Exp Hepatol, 4, 117, 10.1016/j.jceh.2014.06.001 Ford, 2014, Simplification of antiviral hepatitis C virus therapy to support expanded access in resource-limited settings, J Hepatol, 61, S132, 10.1016/j.jhep.2014.09.019 Hatzakis, 2015, The present and future disease burden of hepatitis C virus (HCV) infections with today's treatment paradigm – volume 2, J Viral Hepat, 22, 26, 10.1111/jvh.12351 Wedemeyer, 2015, Estimates on HCV disease burden worldwide – filling the gaps, J Viral Hepat, 22, 1, 10.1111/jvh.12371 Chen, 2013, Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies, Gastroenterology, 144, 1450, 10.1053/j.gastro.2013.02.039 Lawitz, 2013, High concordance of SVR4, SVR12 and SVR24 in patients with HCV infection who have received treatment with sofosbuvir, J Hepatol, 58, S229, 10.1016/S0168-8278(13)60850-8 Tanaka, 2000, Evaluation of a new enzyme immunoassay for hepatitis C virus (HCV) core antigen with clinical sensitivity approximating that of genomic amplification of HCV RNA, Hepatology, 32, 388, 10.1053/jhep.2000.9112 Chakravarti, 2013, Hepatitis C virus core antigen assay: can we think beyond convention in resource limited settings?, Braz J Infect Dis, 17, 369, 10.1016/j.bjid.2012.10.028 Cresswell, 2015, Hepatitis C core antigen testing: a reliable, quick, and potentially cost-effective alternative to hepatitis C polymerase chain reaction in diagnosing acute hepatitis C virus infection, Clin Infect Dis, 60, 263, 10.1093/cid/ciu782 Moini, 2013, Hepatitis C virus (HCV) infection rate among seronegative hemodialysis patients screened by two Methods; HCV core antigen and polymerase chain reaction, Hepat Mon, 13, e9147, 10.5812/hepatmon.9147 Mixson-Hayden, 2015, Performance of architect HCV core antigen test with specimens from US plasma donors and injecting drug users, J Clin Virol, 66, 15, 10.1016/j.jcv.2015.02.015 Vermehren, 2012, Clinical utility of the architect HCV Ag assay for early treatment monitoring in patients with chronic hepatitis C genotype 1 infection, J Clin Virol, 55, 17, 10.1016/j.jcv.2012.05.008 Daniel, 2007, Significance of the hepatitis C virus (HCV) core antigen as an alternative plasma marker of active HCV infection, Int J Med Microbiol, 25, 37, 10.4103/0255-0857.31060 Tillmann, 2014, Hepatitis C virus core antigen testing: role in diagnosis, disease monitoring and treatment, World J Gastroenterol, 20, 6701, 10.3748/wjg.v20.i22.6701 Reyes-Mendez, 2014, Comparison of two diagnostic algorithms for the identification of patients with HCV viremia using a new HCV antigen test, Ann Hepatol, 13, 337, 10.1016/S1665-2681(19)30862-2 Sivaprasad, 2012, The distribution of genotype and allelic frequency of IL28B gene polymorphisms in Andhra Pradesh, India, J Clin Exp Hepatol, 2, 112, 10.1016/S0973-6883(12)60098-X Lawitz, 2013, Sofosbuvir for previously untreated chronic hepatitis C infection, N Engl J Med, 368, 1878, 10.1056/NEJMoa1214853 EASL-ALEH, 2015, Clinical practice guidelines: non-invasive tests for evaluation of liver disease severity and prognosis, J Hepatol, 63, 237, 10.1016/j.jhep.2015.04.006 Bonder, 2015, Contemporary assessment of hepatic fibrosis, Clin Liver Dis, 19, 123, 10.1016/j.cld.2014.09.007 Messina, 2015, Global distribution and prevalence of hepatitis C virus genotypes, Hepatology, 61, 77, 10.1002/hep.27259 Jacobson, 2013, Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options, N Engl J Med, 368, 1867, 10.1056/NEJMoa1214854 Gane, 2013, Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C, N Engl J Med, 368, 34, 10.1056/NEJMoa1208953 Zeuzem, 2014, Sofosbuvir and ribavirin in HCV genotypes 2 and 3, N Engl J Med, 370, 1993, 10.1056/NEJMoa1316145 Foster, 2015, Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with HCV genotype 3 infection and treatment-experienced patients with cirrhosis and HCV genotype 2 infection, Gastroenterology, 10.1053/j.gastro.2015.07.043 Lawitz, 2013, Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial, Lancet Infect Dis, 13, 401, 10.1016/S1473-3099(13)70033-1 Lawitz, 2013, Sofosbuvir in combination with PegIFN and ribavirin for 12 weeks provides high SVR rates in HCV-infected genotype 2 or 3 treatment-experienced patients with and without compensated cirrhosis: results from the LONESTAR-2 study, Hepatology, 58, 1380A Esteban, 2014, Successful retreatment with sofosbuvir-containing regimens for HCV genotype 2 or 3 infected patients who failed prior sofosbuvir plus ribavirin therapy, J Hepatol, 60, S4, 10.1016/S0168-8278(14)60010-6 Kowdley, 2013, Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial, Lancet, 381, 2100, 10.1016/S0140-6736(13)60247-0 Osinusi, 2013, Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial, J Am Med Assoc, 310, 804, 10.1001/jama.2013.109309 Lalezari, 2013, Once daily sofosbuvir plus ribavirin for 12 and 24 weeks in treatment-naive patients with HCV infection: the QUANTUM study, J Hepatol, 58, S346, 10.1016/S0168-8278(13)60847-8 Pearlman, 2015, The combination of simeprevir and sofosbuvir is more effective than that of peginterferon, ribavirin and sofosbuvir for patients with hepatitis C-related Child's class A cirrhosis, Gastroenterology, 148, 762, 10.1053/j.gastro.2014.12.027 Mishra, 2014, FDA perspective on sofosbuvir therapy for patients with chronic hepatitis C virus genotype 1 infection who did not respond to treatment with pegylated interferon and ribavirin, Gastroenterology, 147, 1196, 10.1053/j.gastro.2014.10.027 Jensen, 2014, Safety and efficacy of sofosbuvir-containing regimens for hepatitis C: real world experience in a diverse, longitudinal observational cohort, Hepatology, 60, 219A Dieterich, 2014, Evaluation of sofosbuvir and simeprevir-based regimens in the TRIO network: academic and community treatment of a real-world, heterogeneous population, Hepatology, 60, 220A Ruane, 2015, Sofosbuvir plus ribavirin for the treatment of chronic genotype 4 hepatitis C virus infection in patients of Egyptian ancestry, J Hepatol, 62, 1040, 10.1016/j.jhep.2014.10.044 Doss, 2015, Sofosbuvir plus ribavirin for treating Egyptian patients with hepatitis C genotype 4, J Hepatol, 63, 581, 10.1016/j.jhep.2015.04.023 Sood, 2010, Response to antiviral treatment in patients with chronic hepatitis C with persistently normal liver enzymes, Indian J Gastroenterol, 29, 90, 10.1007/s12664-010-8004-z David, 2010, Infection with hepatitis C virus genotype 3—experience of a tertiary health care center in south India, Indian J Med Microbiol, 28, 155, 10.4103/0255-0857.62495 Tohra, 2011, Prediction of sustained virological response to combination therapy with pegylated interferon alfa and RBV in patients with genotype 3 chronic hepatitis C, Dig Dis Sci, 56, 2449, 10.1007/s10620-011-1770-3 Everson, 2005, Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy, Hepatology, 42, 255, 10.1002/hep.20793 Curry, 2015, Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study, Gastroenterology, 148, 100, 10.1053/j.gastro.2014.09.023 Afdhal, 2014, Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection, N Engl J Med, 370, 1889, 10.1056/NEJMoa1402454 Afdhal, 2014, Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection, N Engl J Med, 370, 1483, 10.1056/NEJMoa1316366 Poordad, 2014, ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis, N Engl J Med, 370, 1973, 10.1056/NEJMoa1402869 Manns, 2014, All-oral dual therapy with daclatasvir and asunaprevir in patients with HCV genotype 1b infection: phase 3 study results, J Hepatol, 60, S524, 10.1016/S0168-8278(14)61461-6 Afdhal, 2014, Sofosbuvir and ribavirin for the treatment of chronic HCV with cirrhosis and portal hypertension with and without decompensation: early virologic response and safety, J Hepatol, 60, S28, 10.1016/S0168-8278(14)60070-2 Akhtar, 2015, Cirrhosis regression in hepatitis C patients with sustained virological response after antiviral therapy: a meta-analysis, Liver Int, 35, 30, 10.1111/liv.12576 Ruiz, 2015, Patient with decompensated hepatitis C virus-related cirrhosis delisted for liver transplantation after successful sofosbuvir-based treatment, Liver Transpl, 21, 408, 10.1002/lt.24051 Flamm, 2014, Ledipasvir/sofosbuvir with ribavirin for the treatment of HCV in patients with decompensated cirrhosis: preliminary results of a prospective, multicenter study, Hepatology, 60, 320A Samuel, 2003, Interferon-alpha 2b plus RBV in patients with chronic hepatitis C after liver transplantation: a randomized controlled study, Gastroenterology, 124, 642, 10.1053/gast.2003.50095 Carrion, 2007, Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study, Gastroenterology, 132, 1746, 10.1053/j.gastro.2007.03.041 Berenguer, 2008, Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with RBV, J Hepatol, 49, 274, 10.1016/j.jhep.2008.05.002 Berenguer, 2008, Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation, Am J Transplant, 8, 679, 10.1111/j.1600-6143.2007.02126.x Charlton, 2015, Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation, Gastroenterology, 148, 108, 10.1053/j.gastro.2014.10.001 Forns, 2015, Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C following liver transplantation, Hepatology, 10.1002/hep.27681 Graham, 2001, Influence of human immunodeficiency virus infection on the course of hepatitis C infection: a meta-analysis, Clin Infect Dis, 33, 562, 10.1086/321909 Soriano, 2008, Antiretroviral drugs and liver injury, AIDS, 22, 1, 10.1097/QAD.0b013e3282f0e2fd Opravil, 2008, Effect of baseline CD4 cell count on the efficacy and safety of peginterferon Alfa-2a (40kD) plus ribavirin in patients with HIV/hepatitis C virus coinfection, J Acquir Immune Defic Syndr, 47, 36, 10.1097/QAI.0b013e31815ac47d Soriano, 2002, Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV International Panel, AIDS, 16, 813, 10.1097/00002030-200204120-00001 Molina, 2015, Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study, Lancet, 385, 1098, 10.1016/S0140-6736(14)62483-1 Labarga, 2015, Liver fibrosis progression despite HCV cure with antiviral therapy in HIV-HCV coinfected patients, Antivir Ther, 20, 329, 10.3851/IMP2909 Saravanan, 2009, Hepatitis B virus and hepatitis C virus dual infection among patients with chronic liver disease, J Microbiol Immunol Infect, 42, 122 Chakravarti, 2005, Characteristics of dual infection of hepatitis B and C viruses among patients with chronic liver disease: a study from tertiary care hospital, Trop Gastroenterol, 26, 183 Xess, 2001, Prevalence of hepatitis B and hepatitis C virus coinfection in chronic liver disease, Indian J Pathol Microbiol, 44, 253 Jamma, 2010, Current concepts of HBV/HCV coinfection: coexistence, but not necessarily in harmony, Curr Hepat Rep, 9, 260, 10.1007/s11901-010-0060-4 Liu, 2012, The influence of hepatitis B virus on antiviral treatment with interferon and ribavirin in Asian patients with hepatitis C virus/hepatitis B virus coinfection: a meta-analysis, Virol J, 9, 186, 10.1186/1743-422X-9-186 Donato, 1998, A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma, Int J Cancer, 75, 347, 10.1002/(SICI)1097-0215(19980130)75:3<347::AID-IJC4>3.0.CO;2-2 Potthoff, 2008, The HEP-NET B/C co-infection trial: a prospective multicenter study to investigate the efficacy of pegylated interferon-alpha2b and ribavirin in patients with HBV/HCV coinfection, J Hepatol, 49, 688, 10.1016/j.jhep.2008.03.028 Tan, 2001, Safety of interferon and RBV therapy in haemodialysis patients with chronic hepatitis C: results of a pilot study, Nephrol Dial Transplant, 16, 193, 10.1093/ndt/16.1.193 Mousa, 2004, Alpha-interferon with RBV in the treatment of hemodialysis patients with hepatitis C, Transplant Proc, 36, 1831, 10.1016/j.transproceed.2004.07.025 Bruchfeld, 2006, Pegylated interferon and RBV treatment for hepatitis C in haemodialysis patients, J Viral Hepat, 13, 316, 10.1111/j.1365-2893.2005.00680.x Rendina, 2007, The treatment of chronic hepatitis C with peginterferon alfa-2a (40kDa) plus RBV in haemodialysed patients awaiting renal transplant, J Hepatol, 46, 768, 10.1016/j.jhep.2006.12.016 Amarapurkar, 2007, Monotherapy with peginterferon alpha-2b {12kDa} for chronic hepatitis C infection in patients undergoing haemodialysis, Trop Gastroenterol, 28, 16 Duseja, 2012, Treatment of chronic hepatitis C in end stage renal disease: experience at a tertiary care centre, Trop Gastroenterol, 33, 189, 10.7869/tg.2012.47